Market News & Trends
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study
Cocrystal Pharma, Inc. recently announced dosing of the first subjects in a Phase 1 clinical trial of healthy adults evaluating its novel, broad-spectrum, orally administered…
Pharmazz Announces FDA Clearance of an IND Application for Phase 2 Clinical Trial
Pharmazz recently announced US FDA clearance of an Investigational New Drug (IND) application for a Phase 2 clinical trial of centhaquine as an adjuvant to…
Evonik Launches New Technology to Improve Solubility of Oral Small Molecules
Evonik recently announced it now offers EUDRATEC SoluFlow, a new microparticle technology to enhance solubility of active pharmaceutical ingredients in oral drug products…..
Denali Therapeutics Announces Initiation of Phase 1/2 Clinical Trial
Denali Therapeutics Inc. recently announced dosing has begun in a Phase 1/2 clinical trial of DNL593 (PTV:PGRN) for the potential treatment of frontotemporal dementia (FTD)…
Vibalogics Completes Major Milestone in $50-Million Facility Expansion
Vibalogics has recently announced the completion of its expansion project at its GMP facility in Cuxhaven, Germany. The new building features biosafety level (BSL) 2…
Novartis, Voyager Therapeutics Reach License Option Agreement
Novartis recently announced a license option agreement with Voyager Therapeutics, a gene therapy company focused on next-generation adeno-associated virus (AAV) technologies, for three….
Adaptive Research & UBERDOC Announce Collaboration
Adaptive Research and UBERDOC recently announced a collaboration to expand clinical trial access to the physicians and clinical trial sites….
BioNTech & Regeneron Expand Strategic Collaboration
BioNTech SE recently announced the expansion of its strategic collaboration with Regeneron to advance the company’s FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor….
Atossa Therapeutics Announces Issuance of Key US Patent Covering Endoxifen
Atossa Therapeutics, Inc. recently announced the US Patent and Trademark office has issued a new patent further strengthening Atossa’s intellectual property in its proprietary therapy…
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553. The positive final analysis included…
DNAnexus Secures $200-Million Funding to Advance its Biomedical Data-Driven Technology Platform for Precision Medicine
DNAnexus, Inc. recently announced a $200-million financing round to accelerate the global adoption of its technology, translating the world’s complex multi-omics and clinical data into…
Enteris BioPharma Publishes White Paper on Best Practices for Ensuring Content Uniformity in Solid Oral Dosage Manufacturing With HPAPI
Enteris BioPharma, Inc. recently announced the publication of a new white paper, titled HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity. The…
Alcami Adds Additional Formulation Development Capabilities
Alcami recently announced the addition of a 3,800 ft² Non-GMP Formulation Development Laboratory (FDL). The dedicated Non-GMP formulation development space, which is co-located within the…
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor in Human Skin Model of Vitiligo
VYNE Therapeutics Inc. recently announced positive preclinical data in an ex vivo skin model of vitiligo. In the preclinical model, pan-bromodomain and extra-terminal (BET) inhibitor…
Targovax ASA & Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON
Agenus and Targovax ASA recently announced they have entered into a clinical collaboration and supply agreement to combine Targovax’s TG mutant KRAS cancer vaccines with Agenus´s clinically validated….
Harpoon Therapeutics Granted Orphan Drug Designation for Small Cell Lung Cancer Treatment
Harpoon Therapeutics, Inc. recently announced the US FDA has granted Orphan Drug Designation for HPN328, a delta like ligand 3- (DLL3) targeting TriTAC, for the…
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial
Evaxion Biotech A/S has recently now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients…..
Cambrex Expands Biopharmaceutical Services Business
Cambrex recently announced it is significantly expanding its existing biopharmaceutical testing services business. The expansion includes 11 additional cGMP….
Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies
Evonik has boosted its supply of plant-derived cholesterol, one of the most critical components for the manufacture of mRNA vaccines and gene therapies. The large-scale production of….
Exclusive License for Croda to Commercialize SSI’s CAF® Vaccine Adjuvants
Croda International Plc, which uses smart science to improve lives, recently announces it has entered a strategic collaboration with Statens Serum Institut (SSI), the leading…